Sangamo Bio reports promising preliminary trial data on HIV drug

(Reuters) – Sangamo BioSciences Inc reported promising preliminary data from two mid-stage studies on its potential experimental HIV/AIDS therapy. The data showed the drug was safe and well-tolerated, the company said on Friday. The experimental drug, codenamed SB-728-T, is being developed for the functional control of HIV/AIDS. (Reporting by Shailesh Kuber in Bengaluru; Editing by Maju Samuel)
Sexual Health News Headlines – Yahoo! News